A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update.

Authors

• Vicky Makker
• Carol Aghajanian
• Allen L Cohn
• Margarita Romeo
• Raquel Bratos
• Marcia S Brose
• Mark Messing
• Lea Dutta
• Corina E Dutcus
• Jie Huang
• Emmett V Schmidt
• Robert Orlowski
• Matthew H Taylor

Publication/Presentation Date

2-10-2023

Volume

41

Issue

5

First Page

974

Last Page

979

ISSN

1527-7755

Published In/Presented At

Makker, V., Aghajanian, C., Cohn, A. L., Romeo, M., Bratos, R., Brose, M. S., Messing, M., Dutta, L., Dutcus, C. E., Huang, J., Schmidt, E. V., Orlowski, R., & Taylor, M. H. (2023). A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(5), 974–979. https://doi.org/10.1200/JCO.22.01021

Disciplines

Medicine and Health Sciences

PubMedID

36608305

Department(s)

Hematology-Medical Oncology Division

Document Type

Article